[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nutraceuticals Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100609105",false,"NCT07210229","The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study\n* Baseline score of above-average menopause symptom levels on each of the patient reported scales: NRI-MSS (defined as 22+), the MRS scale (defined as 9+), AND 4+ on the MENQoL.\n* Confirmation of presence of hot flashes\n* Estridiol levels within the bottom 35% of normal ranges for their menstrual cycle phase (follicular\u002Fovulation\u002Fluteal) as established by laboratory reference range\n* Biological sex of female; gender identification of woman\n* Aged 40 to 55, inclusive\n* Good general health as evidenced by medical history and screening\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study\n* Still menstruating regularly (defined at least one period every 60 days)\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\n* Pregnant, trying to conceive, or breastfeeding\n* Hysterectomy, uterine ablation, or related procedure\n* Amenorrhea\n* Consumes \\> 8 alcoholic beverages in an average week\n* Currently consumes an ashwagandha supplement or has consumed one regularly (defined as 1x week or more often) within the past 24 months\n* Consumes any hormonal therapies or menopause-related supplements intended to improve symptoms in any way\n* Current or recent (within 60 days) history of taking thyroid medications, hypertensive drugs, CNS depressants, diabetic medications, benzodiazepines, or immunosuppressants\n* Any liver, kidney, hormonal, or cardiovascular disorder\n* Known allergic reactions to any components of the intervention\n* Recent dramatic weight changes (10% change in body weight in the last 6 months)\n* Introducing a new investigational drug or other intervention within 60 days before the start of the study\n* Any change to diet or lifestyle within 60 days before the start of the study (defined as introducing any new exercise activity, joining a gym, starting a new routine, moving to a new home, adjusting dietary habits (e.g. vegetarian, paleo, etc) or discontinuing any habits or diets.\n* Any health or medical condition which, in the primary investigators opinion, may interfere with the conduct of the study","FEMALE","40 Years","55 Years",{"count":18,"type":19},90,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on symptoms of menopause and hormone levels, as compared to a placebo.",[25,26],"Menopausal Hot Flashes","Menopausal Women",[28],"ashwagandha","NOT_YET_RECRUITING","2025-09-29",{"date":32,"type":33},"2025-10-07","ACTUAL",{"date":35,"type":19},"2025-10-01",{"date":37,"type":19},"2026-03-30",{"name":39,"class":40},"Nutraceuticals Research Institute","OTHER",1,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":15,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100586742","NCT06919328","Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+","Absorption and Tolerability of Injectable Administration of Niagen®+, Nicotinamide Riboside Chloride, a Specialized Form of Vitamin B3, as Compared to NAD+: a Double Blinded, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study\n* Lives within 100 miles of the NRI study site\n* Any gender, aged 40-65, inclusive\n* Good general health as evidenced by medical history\n* BMI 25-34.9 kg\u002Fm2\n* Sedentary behavior (defined as \\\u003C20 minutes per day or 100 minutes per week of moderate to vigorous exercise)\n* Demonstrated fatigue (Fatigue Assessment Scale) defined as a below-average score\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\n* Current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or Parkinson's disease\n* ANY chronic illness (pre-disease state acceptable)\n* Out of range phosphate levels at baseline\n* BMI less than 25 or greater than or equal to 35\n* Pregnancy, trying to conceive, or breastfeeding\n* Known allergic reactions to any components of the intervention or related compounds, including any form of B3\n* Positive COVID-19 test within 30 days of the study period\n* Recent dramatic weight changes (10% change in body weight in the last 6 months)\n* Existing usage of a NAD+ or NAD precursor supplement in any form (oral, nasal, patch, or injection\u002FIV administration), including a B-complex supplement, within 60 days of the study, not including multivitamins.\n* Introducing a new medication, supplement, investigational drug, or other intervention (including lifestyle changes) within 60 days of the start of the study.",true,"ALL","65 Years",{"count":52,"type":19},70,[22],"This study evaluates the subjective effects of injection administration of NR on healthy adult populations.",[56],"Healthy Aging",[58],"NAD+","RECRUITING","2025-04-07",{"date":62,"type":33},"2025-04-09",{"date":64,"type":33},"2024-10-31",{"date":66,"type":19},"2025-06-30",{"name":39,"class":40},{"id":69,"slug":4,"hasResults":10,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":48,"sex":14,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100577099","NCT06793891","Effects of Ashwagandha Extract on Stress Levels","The Effectiveness of a Proprietary Ashwagandha Extract on Stress Reduction: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study\n* Self reported high stress\n* Baseline score of above-average stress levels on the NRI-SS\n* Biological sex of woman; gender identification of female\n* Aged 30 to 59, inclusive\n* Good general health as evidenced by medical history and screening\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\n* Pregnancy, trying to conceive, or breastfeeding\n* Currently smokes or vapes (i.e., tobacco, flavored items, marijuana, etc.) or has in the past year\n* Consumes \\> 8 alcoholic beverages in an average week\n* Is a primary caretaker for a child younger than 18 months of age\n* Currently consumes an ashwagandha supplement or has consumed one regularly (defined as 1x week or more often) within the past 24 months\n* Consumes any stress aid, medication, diet, or supplement intended to improve stress in any way\n* Current or recent (within 60 days) history of taking thyroid medications, hypertensive drugs, CNS depressants, diabetic medications, benzodiazepines, or immunosuppressants\n* Any liver or kidney disorder\n* Known allergic reactions to any components of the intervention\n* Positive COVID-19 test within 30 days of the study period\n* Recent dramatic weight changes (10% change in body weight in the last 6 months)\n* Introducing a new investigational drug or other intervention within 60 days before the start of the study\n* Introducing a new lifestyle stress-reduction aid (i.e. physical activity, yoga, etc) within 60 days before the start of the study","30 Years","59 Years",{"count":77,"type":19},60,[22],"The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on stress levels, with secondary outcomes of cognition, energy, and sleep, as compared to a placebo.",[81],"Stress",[83,84,85,86,87],"energy","fatigue","cognition","nutraceuticals","Ashwagandha","2025-01-21",{"date":90,"type":33},"2025-01-27",{"date":92,"type":33},"2024-10-21",{"date":94,"type":19},"2025-04-30",{"name":39,"class":40},""]